---
title: "Plus Therapeutics: Advancing Reyobiq Pipeline and CNSide Commercialization Underpinned by Strong Cash Runway to 2027"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279130937.md"
description: "Analyst Jason McCarthy of Maxim Group has maintained a Buy rating on Plus Therapeutics, with a price target of $1.50, citing the company's advancing pipeline and strong balance sheet. The firm raised additional equity, ensuring operations funding through 2027. Key studies for Reyobiq are progressing, and the CNSide assay is expected to generate revenue by 2026. Lake Street also supports the stock with a Buy rating and a $2.00 price target."
datetime: "2026-03-14T18:05:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279130937.md)
  - [en](https://longbridge.com/en/news/279130937.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279130937.md)
---

# Plus Therapeutics: Advancing Reyobiq Pipeline and CNSide Commercialization Underpinned by Strong Cash Runway to 2027

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Plus Therapeutics, retaining the price target of $1.50.

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Jason McCarthy has given his Buy rating due to a combination of factors tied to Plus Therapeutics’ advancing pipeline and strengthened balance sheet. The company ended the year with sufficient cash and subsequently raised additional equity, which McCarthy believes should fund operations into 2027, supporting key value-driving clinical and commercial milestones.

He highlights the ongoing ReSPECT-LM and ReSPECT-GBM Phase 2 studies of Reyobiq, both of which are progressing toward potentially pivotal or registration-enabling designs, backed by encouraging prior survival data and FDA feedback. In parallel, he views the growing adoption and payer coverage of the CNSide assay—along with clear 2026 commercialization targets—as an emerging revenue opportunity that complements the therapeutic programs and supports a favorable risk‑reward profile for PSTV shares.

In another report released on February 26, Lake Street also maintained a Buy rating on the stock with a $2.00 price target.

### Related Stocks

- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PSTV.US](https://longbridge.com/en/quote/PSTV.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)

## Related News & Research

- [IDEAYA eye cancer drug combo meets main goal of mid-to-late-stage trial](https://longbridge.com/en/news/282524512.md)
- [BUZZ-Street View: Analysts upbeat on Revolution pancreatic cancer drug](https://longbridge.com/en/news/282702171.md)
- [Arcutis Biotherapeutics Targets ZORYVE Expansion, Raises 2026 Outlook and Turns Cash-Flow Positive](https://longbridge.com/en/news/282775123.md)
- [Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at Needham](https://longbridge.com/en/news/282904330.md)
- [FDA Rejection Sparks Questions On Replimune Drug Approval Path](https://longbridge.com/en/news/282577359.md)